Hemodynamic factors limiting the response to transdermal nitroglycerin in severe chronic congestive heart failure
- 1 February 1986
- journal article
- research article
- Published by Elsevier
- Vol. 57 (4) , 260-267
- https://doi.org/10.1016/0002-9149(86)90902-1
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Dose requirements and hemodynamic effects of transdermal nitroglycerin compared with placebo in patients with congestive heart failure.Circulation, 1985
- Failure of transdermal nitroglycerin to improve exercise capacity in patients with angina pectorisJournal of the American College of Cardiology, 1985
- Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure.Circulation, 1985
- Failure of transdermal nitroglycerin to improve chronic stable angina: A randomized, placebo-controlled, double-blind, double crossover trialAmerican Heart Journal, 1984
- Trainsdermal nitroglycerin in angina pectorisThe American Journal of Cardiology, 1984
- Antianginal effects of nitroglycerin patchesThe American Journal of Cardiology, 1984
- Sustained beneficial hemodynamic responses to large doses of transdermal nitroglycerin in congestive heart failure and comparison with intravenous nitroglycerinThe American Journal of Cardiology, 1984
- Hemodynamic and Hormonal Response to Transdermal Nitroglycerin in Normal Subjects and in Patients With Congestive Heart FailureJournal of the American College of Cardiology, 1983
- Physiologic and pharmacologic determinants of vasodilator response: A conceptual framework for rational drug therapy for chronic heart failurePublished by Elsevier ,1982
- Dose requirements of hydralazine in patients with severe chronic congestive heart failureThe American Journal of Cardiology, 1980